The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
Taylor-Dunn Celebrates 75 Years of Industrial Electric Vehicles
Industry leader honors iconic legacy as an industrial EV OEM powering productivity across the globe and its bright…
How to Level Up Your Quality Assurance with Inspection Software
Our company often gets asked how to choose quality inspection software and how to maximize its potential. Quality…
Unlocking the Possibilities of NDE 4.0
A computer that can think for itself presents a polarizing reality. Some see it as an all-encompassing solution,…